Defining the future of treatment for people with immune-mediated diseases

Jaideep is founding CEO of Ouro Medicines. He was most recently part of the founding team of Human Immunology Biosciences (HI-Bio), where he led portfolio development and strategy prior to the acquisition by Biogen. Jaideep was also the program team leader for felzartamab, an anti-CD38 monoclonal antibody, currently in late-stage development for the treatment of immune-mediated kidney diseases. Previously, he was at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D, strategy and business development. He started his career at Vida Ventures as an associate. Jaideep is also a Portfolio Principal at Monograph Capital and an observer on the board of Sudo Biosciences. He completed his PhD at MIT in Biological Engineering and holds a BS in Bioengineering from UCLA.

Neely Mozaffarian, MD, PhD, is the Chief Medical Officer at Ouro Medicines, with over 20 years of research experience in autoimmune and autoinflammatory diseases. Prior to Ouro, Neely was the Chief Medical Officer at GentiBio and Atomwise, with large pharma experience at Johnson & Johnson, Gilead, Eli Lilly, and AbbVie, leading drug development of biologics and small molecules across clinical trial phases 1-4. Neely’s research interests center on restoration of immune homeostasis in autoimmune and inflammatory diseases.  She graduated with honors (Alpha Omega Alpha) from the Medical Scientist Training Program at Albert Einstein College of Medicine in NY, and completed Internal Medicine Residency and Rheumatology Fellowship at the University of Washington in Seattle.

Kevin Baker is an experienced research and development scientist. Most recently he was Chief Development Officer at Pionyr Immunotherapeutics Inc., where he led a team developing monoclonal antibodies and proteins to modulate the tumor microenvironment. Two antibody assets progressed into clinical development. Pionyr was acquired by Ikena Oncology.

Before joining Pionyr, Kevin was SVP of Development Sciences at FivePrime Therapeutics Inc., where he served on the Executive Committee and worked on multiple research programs in immune-oncology, immunology, and metabolism. Under his leadership five programs progressed to IND and into clinical development. FivePrime was acquired by Amgen in 2020.

Kevin spent 5 years at Human Genome Sciences where he headed a research group exploring the role of novel proteins in the immune system. In addition, he was project team leader for an antibody targeting B cell growth factor BAFF. He led the program from research, through IND, and into clinical development in autoimmune disease. The asset was subsequently acquired by GSK and is currently marketed as Benlysta. 

Kevin started his biotech career as a Scientist at Genentech after completing a PhD in molecular genetics at the University of Dundee, Scotland and postdoctoral training in molecular cell biology in Basel, Switzerland.

Christina brings nearly 20 years of pharmaceutical and legal experience to her role as Chief Administrative Officer at Ouro Medicines. Partnering with teams throughout Ouro, she is responsible for various matters, including human resources, public affairs and all legal matters, such as licensing, collaborations, compliance, corporate governance, and intellectual property. Prior to joining Ouro Christina served as General Counsel of Human Immunology Biosciences (HIBio), and before HIBio, as Vice President, Corporate Legal and Assistant Secretary at Gilead Sciences. During her time at HIBio and Gilead, Christina led legal teams supporting operations in the United States and Latin America and was involved in the structuring and execution of numerous acquisitions, divestitures, and strategic collaborations. She started her career at the law firm Wilson Sonsini Goodrich & Rosati.

Christina received her J.D. from Santa Clara University Law School and a bachelor’s degree in Biotechnology from the University of California, Davis.